200 related articles for article (PubMed ID: 18781954)
1. HGF/MET signaling in ovarian cancer.
Zhou HY; Pon YL; Wong AS
Curr Mol Med; 2008 Sep; 8(6):469-80. PubMed ID: 18781954
[TBL] [Abstract][Full Text] [Related]
2. Progressive changes in Met-dependent signaling in a human ovarian surface epithelial model of malignant transformation.
Wong AS; Roskelley CD; Pelech S; Miller D; Leung PC; Auersperg N
Exp Cell Res; 2004 Sep; 299(1):248-56. PubMed ID: 15302591
[TBL] [Abstract][Full Text] [Related]
3. Coexpression of hepatocyte growth factor-Met: an early step in ovarian carcinogenesis?
Wong AS; Pelech SL; Woo MM; Yim G; Rosen B; Ehlen T; Leung PC; Auersperg N
Oncogene; 2001 Mar; 20(11):1318-28. PubMed ID: 11313876
[TBL] [Abstract][Full Text] [Related]
4. Regulation of HGF and c-MET Interaction in Normal Ovary and Ovarian Cancer.
Kwon Y; Godwin AK
Reprod Sci; 2017 Apr; 24(4):494-501. PubMed ID: 27170665
[TBL] [Abstract][Full Text] [Related]
5. Effective inhibition of c-MET-mediated signaling, growth and migration of ovarian cancer cells is influenced by the ovarian tissue microenvironment.
Kwon Y; Smith BD; Zhou Y; Kaufman MD; Godwin AK
Oncogene; 2015 Jan; 34(2):144-53. PubMed ID: 24362531
[TBL] [Abstract][Full Text] [Related]
6. Expression and action of hepatocyte growth factor in human and bovine normal ovarian surface epithelium and ovarian cancer.
Parrott JA; Skinner MK
Biol Reprod; 2000 Mar; 62(3):491-500. PubMed ID: 10684788
[TBL] [Abstract][Full Text] [Related]
7. [Expressions of MACC1, HGF, and C-met protein in epithelial ovarian cancer and their significance].
Zhang RT; Shi HR; Huang HL; Chen ZM; Liu HN; Yuan ZF
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Sep; 31(9):1551-5. PubMed ID: 21945764
[TBL] [Abstract][Full Text] [Related]
8. CAF-derived HGF promotes cell proliferation and drug resistance by up-regulating the c-Met/PI3K/Akt and GRP78 signalling in ovarian cancer cells.
Deying W; Feng G; Shumei L; Hui Z; Ming L; Hongqing W
Biosci Rep; 2017 Apr; 37(2):. PubMed ID: 28258248
[TBL] [Abstract][Full Text] [Related]
9. The Therapeutic Potential of Targeting the HGF/cMET Axis in Ovarian Cancer.
Moran-Jones K
Mol Diagn Ther; 2016 Jun; 20(3):199-212. PubMed ID: 27139908
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic Strategies for Ovarian Cancer in Point of HGF/c-MET Targeting.
Kim HJ
Medicina (Kaunas); 2022 May; 58(5):. PubMed ID: 35630066
[TBL] [Abstract][Full Text] [Related]
11. Targeting the hepatocyte growth factor/Met pathway in cancer.
De Silva DM; Roy A; Kato T; Cecchi F; Lee YH; Matsumoto K; Bottaro DP
Biochem Soc Trans; 2017 Aug; 45(4):855-870. PubMed ID: 28673936
[TBL] [Abstract][Full Text] [Related]
12. A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth.
Marchion DC; Bicaku E; Xiong Y; Bou Zgheib N; Al Sawah E; Stickles XB; Judson PL; Lopez AS; Cubitt CL; Gonzalez-Bosquet J; Wenham RM; Apte SM; Berglund A; Lancaster JM
Oncol Rep; 2013 May; 29(5):2011-8. PubMed ID: 23467907
[TBL] [Abstract][Full Text] [Related]
13. Ovarian surface epithelium: biology, endocrinology, and pathology.
Auersperg N; Wong AS; Choi KC; Kang SK; Leung PC
Endocr Rev; 2001 Apr; 22(2):255-88. PubMed ID: 11294827
[TBL] [Abstract][Full Text] [Related]
14. The potential therapeutic and prognostic impacts of the c-MET/HGF signaling pathway in colorectal cancer.
Parizadeh SM; Jafarzadeh-Esfehani R; Fazilat-Panah D; Hassanian SM; Shahidsales S; Khazaei M; Parizadeh SMR; Ghayour-Mobarhan M; Ferns GA; Avan A
IUBMB Life; 2019 Jul; 71(7):802-811. PubMed ID: 31116909
[TBL] [Abstract][Full Text] [Related]
15. [Effect of hepatocyte growth factor on invasion of ovarian cancer cell line SKOV3 and its signal transduction pathway].
Wang HL; Zhang SL; Lu YM; Jiang JY; Zhu XY
Ai Zheng; 2006 May; 25(5):570-5. PubMed ID: 16687076
[TBL] [Abstract][Full Text] [Related]
16. The HGF-met signaling axis: emerging themes and targets of inhibition.
Steffan JJ; Coleman DT; Cardelli JA
Curr Protein Pept Sci; 2011 Feb; 12(1):12-22. PubMed ID: 21190524
[TBL] [Abstract][Full Text] [Related]
17. Ovarian cancer ascites enhance the migration of patient-derived peritoneal mesothelial cells via cMet pathway through HGF-dependent and -independent mechanisms.
Matte I; Lane D; Laplante C; Garde-Granger P; Rancourt C; Piché A
Int J Cancer; 2015 Jul; 137(2):289-98. PubMed ID: 25482018
[TBL] [Abstract][Full Text] [Related]
18. The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness.
Maggiora P; Lorenzato A; Fracchioli S; Costa B; Castagnaro M; Arisio R; Katsaros D; Massobrio M; Comoglio PM; Flavia Di Renzo M
Exp Cell Res; 2003 Aug; 288(2):382-9. PubMed ID: 12915129
[TBL] [Abstract][Full Text] [Related]
19. MET/HGF pathway in multiple myeloma: from diagnosis to targeted therapy?
Gambella M; Palumbo A; Rocci A
Expert Rev Mol Diagn; 2015; 15(7):881-93. PubMed ID: 25967746
[TBL] [Abstract][Full Text] [Related]
20. Targeting HGF/c-MET Axis in Pancreatic Cancer.
Pothula SP; Xu Z; Goldstein D; Pirola RC; Wilson JS; Apte MV
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33271944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
